Paricalcitol Patent Expiration
Paricalcitol is Used for managing secondary hyperparathyroidism in chronic kidney disease. It was first introduced by Abbvie Inc
Paricalcitol Patents
Given below is the list of patents protecting Paricalcitol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zemplar |
US6136799 (Pediatric) | Cosolvent formulations |
Oct 08, 2018
(Expired) | Abbvie |
| Zemplar |
US6361758 (Pediatric) | Cosolvent formulations |
Oct 08, 2018
(Expired) | Abbvie |
| Zemplar | US6136799 | Cosolvent formulations |
Apr 08, 2018
(Expired) | Abbvie |
| Zemplar | US6361758 | Cosolvent formulations |
Apr 08, 2018
(Expired) | Abbvie |
| Zemplar |
US5597815 (Pediatric) | Prevention of hyperphosphatemia in kidney disorder patients |
Jan 13, 2016
(Expired) | Abbvie |
| Zemplar | US5597815 | Prevention of hyperphosphatemia in kidney disorder patients |
Jul 13, 2015
(Expired) | Abbvie |
| Zemplar |
US5587497 (Pediatric) | 19-nor-vitamin D compounds |
Jun 24, 2014
(Expired) | Abbvie |
| Zemplar | US5587497 | 19-nor-vitamin D compounds |
Dec 24, 2013
(Expired) | Abbvie |
| Zemplar |
US5246925 (Pediatric) | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
Oct 17, 2012
(Expired) | Abbvie |
Paricalcitol's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List